Jason M Broderick

Obese Patients Tend to Have Better Prostate Cancer Outcomes

July 20, 2021

Article

Despite this “obesity paradox,” doctors do not recommend gaining weight with hopes of improving cancer outcomes.

Keytruda-Inlyta Combo Continues to Improve Survival in Kidney Cancer

June 10, 2021

Article

Use of the combination of Keytruda and Inlyta is associated with long-term survival benefits in patients with kidney cancer.

Investigational Therapy Significantly Improves Survival in Patients with Prostate Cancer

June 04, 2021

Article

The addition of an investigational therapy to standard-of-care treatment was associated with a median overall survival of 15.3 months in patients with progressive PSMA-positive metastatic castration-resistant prostate cancer.

Zytiga and Prednisone Plus Erleada Reduces Risk of Disease Progression in Prostate Cancer Subtype

February 12, 2021

Article

The combination of Erleada, Zytiga and the steroid prednisone was associated with a trend toward better survival outcomes in certain patients with chemotherapy-naive metastatic castration-resistant prostate cancer.

FDA Grants Polivy Accelerated Approval for DLBCL

June 10, 2019

Article

The FDA has granted an accelerated approval to Polivy for use in combination with bendamustine and Rituxan for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma who have received at least two prior therapies.

FDA Approves Revlimid/Rituxan Combo for Indolent Non-Hodgkin Lymphoma

May 28, 2019

Article

The Food and Drug Administration has approved the combination regimen of Revlimid plus Rituxan for use in patients with previously-treated follicular lymphoma and marginal zone lymphoma.

FDA Approves Piqray to Treat Breast Cancer

May 25, 2019

Article

The Food and Drug Administration has approved the PI3K inhibitor Piqray (alpelisib) for the treatment of postmenopausal women, and men, with HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer following progression on or after an endocrine-based regimen.

FDA Panel Recommends Against Quizartinib Approval for Acute Myeloid Leukemia

May 15, 2019

Article

The Food and Drug Administration’s Oncologic Drugs Advisory Committee voted against approving a new drug application for quizartinib for adult patients with relapsed/refractory FLT3-ITD–positive AML.

Reduced Treatment Proves Safer and Just as Effective in Younger Patients With Diffuse Large B-Cell Lymphoma

March 03, 2019

Article

Treating younger patients with low-risk diffuse large B-cell lymphoma (DLBCL) with two fewer front-line cycles of standard treatment greatly reduced toxicity without sacrificing effi­cacy.

FDA Grants Priority Review to Revlimid Plus Rituxan for Indolent Non-Hodgkin Lymphoma

February 27, 2019

Article

The Food and Drug Administration granted a priority review to Revlimid (lenalidomide) plus Rituxan (rituximab) for the treatment of patients with previously treated follicular lymphoma and marginal zone lymphoma.